WO2016046734A3 - Compounds and compositions for treatment of tuberculosis - Google Patents

Compounds and compositions for treatment of tuberculosis Download PDF

Info

Publication number
WO2016046734A3
WO2016046734A3 PCT/IB2015/057280 IB2015057280W WO2016046734A3 WO 2016046734 A3 WO2016046734 A3 WO 2016046734A3 IB 2015057280 W IB2015057280 W IB 2015057280W WO 2016046734 A3 WO2016046734 A3 WO 2016046734A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
tuberculosis
treatment
pharmaceutical compositions
compositions
Prior art date
Application number
PCT/IB2015/057280
Other languages
French (fr)
Other versions
WO2016046734A2 (en
Inventor
Alan Gilbert CHRISTOFFELS
Ekow OPPON
Ruben Earl Ashley CLOETE
Original Assignee
University Of The Western Cape
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of The Western Cape filed Critical University Of The Western Cape
Publication of WO2016046734A2 publication Critical patent/WO2016046734A2/en
Publication of WO2016046734A3 publication Critical patent/WO2016046734A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to compounds which have a higher binding affinity than the natural substrate or natural ligand of three protein targets involved in Mycobacterium tuberculosis metabolic pathways. The protein targets being cytidylate kinase (cmk), nicotinate mononucleotide adenylyltransferase (nadD) and ATP synthase epsilon chain (AtpC). The invention further relates to pharmaceutical compositions containing the compounds, uses of the pharmaceutical compositions and methods of treatment of tuberculosis.
PCT/IB2015/057280 2014-09-22 2015-09-22 Compounds and compositions for treatment of tuberculosis WO2016046734A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA201406920 2014-09-22
ZA2014/06920 2014-09-22

Publications (2)

Publication Number Publication Date
WO2016046734A2 WO2016046734A2 (en) 2016-03-31
WO2016046734A3 true WO2016046734A3 (en) 2016-06-30

Family

ID=54292854

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/057280 WO2016046734A2 (en) 2014-09-22 2015-09-22 Compounds and compositions for treatment of tuberculosis

Country Status (1)

Country Link
WO (1) WO2016046734A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10457682B2 (en) 2016-10-21 2019-10-29 Oregon Health & Science University Small molecules that bind MR1
CN108267589B (en) * 2016-12-30 2020-10-23 首都医科大学附属北京胸科医院 Application of mycobacterium tuberculosis protein in preparing product for diagnosing latent tuberculosis infected person and/or active tuberculosis
US11364276B2 (en) 2019-03-26 2022-06-21 National Guard Health Affairs Antiviral peptides for treatment of the middle east respiratory syndrome

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09208473A (en) * 1996-02-06 1997-08-12 Yamasa Shoyu Co Ltd In vivo cholesterol metabolic regulator and its use
US20040224039A1 (en) * 2003-02-12 2004-11-11 Donald Brucker Compositions and methods for the treatment of diseases and disorder associated with oxidative damage
CN1660126A (en) * 2005-01-03 2005-08-31 杨喜鸿 Medication of combination of sodium cytidine triphosphate and ebselen
WO2005123097A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder
WO2006002422A2 (en) * 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
WO2006072809A2 (en) * 2003-10-31 2006-07-13 Robarts Research Institute Formulations that optimize intracellular concentration of nicotinamide adenine (nad+) and methods of use to protect cells and treat diseases and conditions
WO2007059762A1 (en) * 2005-11-25 2007-05-31 Gisela Susilo Combination preparations containing physiological cell membrane constituents including phosphatidylserine, choline and a pyrimidine nucleoside/nucleotide
WO2013047567A1 (en) * 2011-09-27 2013-04-04 参天製薬株式会社 Corneal epithelial cell death inhibitor containing flavin adenine dinucleotide or salt thereof as active ingredient
CN103044509A (en) * 2013-01-05 2013-04-17 宁辉 Gamma-cytidine-5'-disodium triphosphate crystal compound, and preparation method and drug composition of crystal compound
CN103110602A (en) * 2013-03-12 2013-05-22 成都天台山制药有限公司 Disodium adenosine triphosphate troche medical composition

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09208473A (en) * 1996-02-06 1997-08-12 Yamasa Shoyu Co Ltd In vivo cholesterol metabolic regulator and its use
US20040224039A1 (en) * 2003-02-12 2004-11-11 Donald Brucker Compositions and methods for the treatment of diseases and disorder associated with oxidative damage
WO2006072809A2 (en) * 2003-10-31 2006-07-13 Robarts Research Institute Formulations that optimize intracellular concentration of nicotinamide adenine (nad+) and methods of use to protect cells and treat diseases and conditions
WO2005123097A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder
WO2006002422A2 (en) * 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
CN1660126A (en) * 2005-01-03 2005-08-31 杨喜鸿 Medication of combination of sodium cytidine triphosphate and ebselen
WO2007059762A1 (en) * 2005-11-25 2007-05-31 Gisela Susilo Combination preparations containing physiological cell membrane constituents including phosphatidylserine, choline and a pyrimidine nucleoside/nucleotide
WO2013047567A1 (en) * 2011-09-27 2013-04-04 参天製薬株式会社 Corneal epithelial cell death inhibitor containing flavin adenine dinucleotide or salt thereof as active ingredient
CN103044509A (en) * 2013-01-05 2013-04-17 宁辉 Gamma-cytidine-5'-disodium triphosphate crystal compound, and preparation method and drug composition of crystal compound
CN103110602A (en) * 2013-03-12 2013-05-22 成都天台山制药有限公司 Disodium adenosine triphosphate troche medical composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C. THUM ET AL: "The Rv1712 Locus from Mycobacterium tuberculosis H37Rv Codes for a Functional CMP Kinase That Preferentially Phosphorylates dCMP", JOURNAL OF BACTERIOLOGY, vol. 191, no. 8, 30 January 2009 (2009-01-30), US, pages 2884 - 2887, XP055269642, ISSN: 0021-9193, DOI: 10.1128/JB.01337-08 *
DATABASE WPI Week 200610, Derwent World Patents Index; AN 2006-091153, XP002757367 *
DATABASE WPI Week 201326, Derwent World Patents Index; AN 2013-F10857, XP002757368 *

Also Published As

Publication number Publication date
WO2016046734A2 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
IL292512A (en) Crispr–cas–related methods, compositions and components for cancer immunotherapy
EP4331585A3 (en) Inhibitors of ret
UA117976C2 (en) Aminopyrimidinyl compounds as jak inhibitors
PH12018500792A1 (en) Benzolactam compounds as protein kinase inhibitors
MX2018006973A (en) Humanized anti-cd73 antibodies.
MX2018009773A (en) Heteroaryl inhibitors of pad4.
EP3679063A4 (en) Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers
PH12016502213A1 (en) Novel compositions, uses and methods for making them
EP4252853A3 (en) Compounds and compositions for treating hematological disorders
WO2009064486A3 (en) Inhibitors of pim protein kinases, compositions, and methods for treating cancer
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
TW200801008A (en) Protein kinase inhibitors
MX336726B (en) Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors.
WO2017160116A3 (en) Novel compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same
PH12017500881A1 (en) Aurora a kinase inhibitor
WO2016198698A8 (en) P38 inhibitors for the treatment and prophylaxis of liver cancer
WO2016046734A3 (en) Compounds and compositions for treatment of tuberculosis
WO2013120022A3 (en) Treatment of hypoglycemia
EA201691549A1 (en) ARYLACTAM KINASE INHIBITORS
EP3847283A4 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
WO2018218197A3 (en) Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
IL272067A (en) Compounds, compositions, and methods for treating t-cell acute lymphoblastic leukemia
WO2009099625A3 (en) Cyclopamine tartrate salt and uses thereof
MX2017011116A (en) Novel compositions, uses and methods for making them.
WO2018189661A3 (en) Methods and compounds for treating diabetes

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15778740

Country of ref document: EP

Kind code of ref document: A2